Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) Revenue
Zoetis Inc.'s revenue for fiscal 2025 was $9.5B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $9.5B. Over the past ten years it has ranged from $4.8B (fiscal 2015) to $9.5B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. Zoetis Inc. ranks 6th of 75 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $9.5B | 2.28% |
| FY2024 | $9.3B | 8.33% |
| FY2023 | $8.5B | 5.74% |
| FY2022 | $8.1B | 3.91% |
| FY2021 | $7.8B | 16.49% |
| FY2020 | $6.7B | 6.63% |
| FY2019 | $6.3B | 7.47% |
| FY2018 | $5.8B | 9.76% |
| FY2017 | $5.3B | 8.57% |
| FY2016 | $4.9B | 2.58% |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $2.5B | 9.11% |
| Mar 2026 | $2.3B | (5.55%) |
| Dec 2025 | $2.4B | (0.21%) |
| Sep 2025 | $2.4B | (2.99%) |
| 42 more quarters | Free account |
Against its own ten years
Low $4.8B
High $9.5B
Ten-year median
$6.7B
Current reading's percentile
100
Revenue against peers
| Company | Revenue |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $30.0B |
| HLN Haleon PLC Sponsored ADR compare | $18.1B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $17.3B |
| VTRS Viatris Inc. compare | $14.7B |
| ZTS Zoetis Inc. | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.4B |
| UTHR United Therapeutics Corporation compare | $3.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ZTS
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement